Translate Bio Announces Second Quarter 2019 Financial Results and Provides Corporate Update
31 juil. 2019 06h51 HE
|
Translate Bio, Inc.
-- Announced interim results from single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis (CF) -- -- Received FDA clearance to advance 2nd program into clinical development,...
Translate Bio Announces Interim Results from Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis
31 juil. 2019 06h50 HE
|
Translate Bio, Inc.
-- MRT5005 was generally well tolerated at low and mid-dose levels; no serious adverse events reported at any dose level -- -- Marked increases in ppFEV1 (percent predicted forced expiratory volume...
Translate Bio Appoints George Demetri, M.D., to its Board of Directors
15 juil. 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Present at the Jefferies 2019 Healthcare Conference
28 mai 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces First Quarter 2019 Financial Results and Provides Corporate Update
09 mai 2019 16h23 HE
|
Translate Bio, Inc.
-- Completed dosing in single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis; data expected 3Q19 -- LEXINGTON, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq:...
Translate Bio Announces $47.5 Million Private Placement
01 mai 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Oral Presentation of mRNA Therapeutics in Models of Metabolic Disorders at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
29 avr. 2019 08h45 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Appoints Robert Plenge, M.D., Ph.D., to its Board of Directors
11 avr. 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Presents Preclinical Data Supporting MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting
08 avr. 2019 16h05 HE
|
Translate Bio, Inc.
-- MRT5201 was efficiently delivered to the liver of a mouse model of OTC deficiency -- -- Preclinical data demonstrated a single IV dose of MRT5201 was sufficient to protect against hyperammonemia...
Translate Bio Appoints Richard Wooster as Chief Scientific Officer
08 avr. 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...